İNANÇ, G. N. Et Al. 2018. Is there any difference in RA patients for methotrexate use vs leflunomide use as a concomitant treatment with biological and targeted synthetic DMARDS in TURKBİO Registry?. EULAR 2018 , (Amsterdam, Netherlands), 611.

İNANÇ, G. N., ÖZEN, G., YALÇINKAYA, Y., DALKILIÇ, H. E., KOCA, S. S., CAN, G., ... KARATAŞ, A.(2018). Is there any difference in RA patients for methotrexate use vs leflunomide use as a concomitant treatment with biological and targeted synthetic DMARDS in TURKBİO Registry? . EULAR 2018 (pp.611). Amsterdam, Netherlands

İNANÇ, GÜZİDE Et Al. "Is there any difference in RA patients for methotrexate use vs leflunomide use as a concomitant treatment with biological and targeted synthetic DMARDS in TURKBİO Registry?," EULAR 2018, Amsterdam, Netherlands, 2018

İNANÇ, GÜZİDE N. Et Al. "Is there any difference in RA patients for methotrexate use vs leflunomide use as a concomitant treatment with biological and targeted synthetic DMARDS in TURKBİO Registry?." EULAR 2018 , Amsterdam, Netherlands, pp.611, 2018

İNANÇ, G. N. Et Al. (2018) . "Is there any difference in RA patients for methotrexate use vs leflunomide use as a concomitant treatment with biological and targeted synthetic DMARDS in TURKBİO Registry?." EULAR 2018 , Amsterdam, Netherlands, p.611.

@conferencepaper{conferencepaper, author={GÜZİDE NEVSUN İNANÇ Et Al. }, title={Is there any difference in RA patients for methotrexate use vs leflunomide use as a concomitant treatment with biological and targeted synthetic DMARDS in TURKBİO Registry?}, congress name={EULAR 2018}, city={Amsterdam}, country={Netherlands}, year={2018}, pages={611} }